MetabolicPreliminary grade

Liraglutide

Saxenda / Victoza

The original once-daily GLP-1 — FDA-approved, strong cardiovascular data, but largely superseded by weekly semaglutide.

Verdict — B · Viable

Strong, well-replicated evidence and an established safety record, but daily dosing is inferior to weekly semaglutide and the gray-market supply carries the same counterfeit risks. A viable B-grade workhorse — obtain it through a licensed provider.

PepScore / 100

BViable

How we compute this →

Overview

Liraglutide is a daily GLP-1 receptor agonist FDA-approved for obesity (Saxenda, 2014) and type-2 diabetes (Victoza, 2010), with robust RCT evidence including the SCALE program and the LEADER cardiovascular outcomes trial. It was the category standard before semaglutide, and while the science is strong, the daily injection burden and gray-market supply issues mirror the rest of the GLP-1 class.

PepScore Breakdown — the four axes

Evidence

35% weight

88/100

How strong is the published human science?

Human data depth36/40

Regulatory & registry status27/30

Reproducibility & consistency17/20

Mechanism characterized in humans8/10

Sourcing & COA

30% weightOur moat

59/100

Can a buyer obtain an independently-verified, high-purity version? — our proprietary layer.

Independent 3rd-party testing20/35

Verified purity %18/30

COA transparency & batch traceability11/20

Multi-vendor verified availability10/15

Safety & Risk

25% weight

50/100

What is the real-world harm potential?

Documented AEs / toxicity20/40

Contraindication breadth12/25

Regulatory warnings8/20

Therapeutic index / margin10/15

Practicality

10% weight

67/100

How easy is it to actually run a verified version?

Verified-source availability26/35

Cost / value per cycle14/25

Reconstitution & administration18/25

Storage & stability9/15

Sources & Citations

Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.

Want a clinical path?

Talk to a licensed provider about Liraglutide and whether it's appropriate for your situation.

Talk to a Provider ↗

Telehealth. Not medical advice — for educational purposes.

PepScore68/100 · B

Last gradedJune 28, 2026

Next re-grade triggerGeneric availability would improve Practicality/cost; a verified gray-market COA sweep would move Sourcing.

Price Index Vendor Grades Providers COA Lookup All Rankings

Get the PepEvolution Dispatch

Monthly COA findings, vendor changes, and new grades. Research/educational only — no spam.

Free. Unsubscribe anytime. Research/educational content only.

Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.